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Abstract
Background: A novel porcine deltacoronavirus (PDCoV), also known as porcine coronavirus HKU15, was reported in
China in 2012 and identified in the U.S. in early 2014. Since then, PDCoV has been identified in a number of U.S.
states and linked with clinical disease including acute diarrhea and vomiting in the absence of other identifiable
pathogens. Since PDCoV was just recently linked with clinical disease, few specific antibody-based reagents were
available to assist in diagnosis of PDCoV and limited serological capabilities were available to detect an antibody
response to this virus. Therefore, the overall objective of this project was to develop and validate selected
diagnostic reagents and assays for PDCoV antigen and antibody detection.
Results: The nucleoprotein of PDCoV was expressed as a recombinant protein and purified for use as an antigen to
immunize mice for polyclonal, hyperimmune sera and monoclonal antibody (mAb) production. The resulting mAbs
were evaluated for use in fluorescent antibody staining methods to detect PDCoV infected cells following virus
isolation attempts and for immunohistochemistry staining of intestinal tissues of infected pigs. The same antigen
was used to develop serological tests to detect the antibody response to PDCoV in pigs following infection. Serum
samples from swine herds with recent documentation of PDCoV infection and samples from expected naïve herds
were used for initial assay optimization. The tests were optimized in a checkerboard fashion to reduce signal to
noise ratios using samples of known status. Statistical analysis was performed to establish assay cutoff values and
assess diagnostic sensitivities and specificities. At least 629 known negative serum samples and 311 known positive
samples were evaluated for each assay. The enzyme linked immunosorbent assay (ELISA) showed diagnostic
sensitivity (DSe) of 96.1 % and diagnostic specificity (DSp) of 96.2 %. The fluorescent microsphere immunoassay
(FMIA) showed a DSe of 95.8 % and DSp of 98.1 %. Both ELISA and FMIA detected seroconversion of challenged
pigs between 8–14 days post-infection (DPI). An indirect fluorescent antibody (IFA) test was also developed using
cell culture adapted PDCoV for comparative purposes.
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Conclusion: These new, specific reagents and serological assays will allow for improved diagnosis of PDCoV. Since
many aspects of PDCoV infection and transmission are still not fully understood, the reagents and assays developed
in this project should provide valuable tools to help understand this disease and to aid in the control and
surveillance of porcine deltacoronavirus outbreaks.
Keywords: Porcine deltacoronavirus (PDCoV), Monoclonal antibodies, Serology, ELISA, Fluorescent microsphere
immunoassay (FMIA)
Background
Coronaviruses are enveloped, positive sense RNA viruses
divided among several genera, including Alphacorona-
virus, Betacoronavirus, Gammacoronavirus and the re-
cently described genus Deltacoronavirus. A novel porcine
deltacoronavirus (PDCoV) was reported in China in 2012
and designated HKU15 [1]. Other important porcine
coronaviruses include porcine epidemic diarrhea virus
(PEDV), transmissible gastroenteritis virus (TGEV) and
porcine respiratory coronavirus (PRCV); and are members
of the genus Alphacoronavirus [2]. In February 2014, the
Ohio Department of Agriculture announced the identifi-
cation of PDCoV in swine feces at five farms in Ohio and
associated with enteric disease similar to PEDV in the U.S.
[3]. Since then, PDCoV has been identified in numerous
U.S. states and Canada, linked with apparent clinical dis-
ease including acute diarrhea and vomiting in the absence
of other identifiable pathogens. According to field obser-
vations in the U.S., PDCoV infections cause less severe
clinical disease than PEDV, but analysis of the field data is
complicated since co-infections with PEDV or other path-
ogens are common. PDCoV is currently diagnosed by real
time PCR and clinical symptoms [1, 4].
The severity of disease in both gnotobiotic and con-
ventional piglets has further defined the pathogenicity
and pathogenesis of the virus [5–7]. PDCoV causes diar-
rhea and vomiting in all age groups and mortality in
nursing pigs but the mortality rates are less than that
shown in cases of PEDV. Previously, there was little in-
formation about deltacoronavirus infections in pigs and
only one surveillance study from Hong Kong reported
its detection in pigs prior to its emergence in the U.S.
The virus had not been reported to be associated with
clinical disease in China. The newly emergent strain
found on the Ohio farms, PorCoV HKU15 OH 1987, is
closely related to the 2 strains from China, but it is un-
known how this virus was introduced into the US [3].
Recently, Jung et al. [7] developed in-situ hybridization
and immunofluorescence staining techniques to demon-
strate the areas of PDCoV replication in tissues of infected
pigs. The OH-FD22 and OH-FD100 PDCoV strains were
confirmed as causing an acute infection through the entire
intestine, but primarily the jejunum and ileum, and clinic-
ally lead to severe diarrhea and vomiting. Clinical signs
and pathological features of PDCoV-infected pigs resem-
ble those of PEDV and TGEV infections. Effective differ-
ential diagnosis between PDCoV, PEDV, and TGEV is
important to control the diseases.
Polymerase chain reaction (PCR) assays were quickly
developed for the detection of PDCoV infections follow-
ing the initial U.S. identification in 2014 but available
serological assays are limited. Thachil et al. [8] devel-
oped an indirect anti-PDCoV IgG enzyme-linked im-
munosorbent assay (ELISA) based on the S1 portion of
the spike protein. Although this assay was shown to be a
highly sensitive (91 %) and specific test (95 %), there is
need for other ELISAs utilizing alternative antigen tar-
gets, such as the nucleoprotein of PDCoV, to serve as
primary serological surveillance or confirmatory assays.
As noted in Thachil’s research, several serum samples
collected in 2010 were found positive for PDCoV
antibody by their ELISA, but all those collected in
2011 and 2012 tested negative by that assay. This
finding is interesting since PDCoV was not thought
to be circulating in North America prior to late 2013
[7, 9]. Therefore, availability of several serological
assay formats targeting different viral antigens can be
valuable as confirmatory assays in the investigation of
unexpected laboratory findings.
Since no specific antibody-based reagents were avail-
able to assist in diagnosis of PDCoV, one purpose of the
current study was to develop readily available reagents
for detection of PDCoV antigen in diagnostic tests, such
as virus isolation, immunohistochemistry and fluores-
cent antibody techniques. Serological tests for the de-
tection of antibody responses to PDCoV were also
very limited. Therefore, another objective of this study
was to develop and optimize several serological assays
including an indirect ELISA, a fluorescent micro-
sphere immunoassay (FMIA), and an indirect fluores-
cent antibody (IFA) test.
Both specific antibody-based reagents and serological
tests are essential for the further study and control of
PDCoV and the differentiation of PDCoV infection from
other related diseases such as PEDV or TGEV. The tools
developed during the course of this study can be applied
to many ongoing and future studies to better understand
and control PDCoV.
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Methods
Serum samples
Samples used for optimization and validation of the
PDCoV ELISA and FMIA assays included samples from a
large PDCoV challenge study associated with National
Pork Board (NPB) research project 14–182. These samples
and samples from another group of 30 pigs which were
collected near the time of initial field exposure to PDCoV
and 28 days later were used in a time course study.
For further validation and assessment of diagnostic
sensitivity (DSe) and diagnostic specificity (DSp), sam-
ples of known PDCoV serostatus were used (n = 940).
The expected positive samples were submitted field
serum samples (n = 311) from herds previously testing
PDCoV positive by PCR at least 3 weeks prior to sample
collection. Expected negative samples included archived
experimental serum collected prior to 2009 (n = 108)
and field samples from high-health herds with no known
history of PDCoV exposure (n = 521). The total number
of expected negative samples was 629.
Viruses and cells
Swine testicle (ST) cells were cultured in Eagle’s mini-
mum essential medium (MEM; Gibco BRL Life Tech-
nologies) supplemented with 10 % fetal bovine serum
(FBS), and antibiotics (100 units/ml penicillin and 20 g/
ml streptomycin). Cells were maintained at 37 °C in a
humidified 5 % CO2 incubator. Cell culture adapted
PDCoV was provided by the National Veterinary Ser-
vices Laboratories, designated porcine coronavirus
HKU15 strain Michigan/8977/2014 (GenBank accession
KM012168). PDCoV was propagated on ST cells utiliz-
ing 0.8 μg/ml trypsin (TPCK-treated, bovine derived
(Sigma, St. Louis, MO)) in the inoculation and mainten-
ance media. Virus infected cells were harvested 24–48 h
after inoculation, when significant cytopathic effect
(CPE) was noted.
Antigen production
The antigen used for the FMIA and indirect ELISA val-
idation was a recombinantly expressed, full length,
PDCoV nucleoprotein (NP). RNA isolated from semi-
purified cultured virus corresponding to the PDCoV-NP
was amplified by reverse transcriptase polymerase chain
reaction (RT-PCR) and resulting DNA cloned into the
pET-28a protein expression vector (Novagen, Madison,






The NP gene was prokaryotically expressed as an in-
soluble 41 kDa, 6x polyhistidine-tagged, fusion protein
then purified according to previously described methods
[10]. Purified protein was analyzed by sodium dodecyl
sulfate- polyacrylamide gel electrophoresis (SDS-PAGE)
to determine purity and linear integrity. The expressed
PDCoV NP was recognized in Western blotting by con-
valescent serum and two separate monoclonal antibodies
developed in our laboratory were used to confirm the
specificity of the proteins.
Refolding of the PDCoV NP purified protein
The purified protein was refolded by first solubilizing
the recombinant protein expressed as insoluble inclusion
bodies in E. coli. Briefly, the protein was solubilized in
50 mM 3-(Cyclohexylamino)-1-propanesulfonic acid
(CAPS buffer, pH 11.0) containing 1.0 % N-lauroylsarco-
sine and 1.0 mM DTT. The protein was then dialyzed
overnight at 4 °C in 20 mM Tris–HCl pH 8.5 containing
0.1 mM DTT to encourage correct disulfide bond for-
mation and subsequent refolding of the protein. A
second dialysis step was done in phosphate buffered sa-
line (PBS) to remove excess reducing agent. Testing of
the re-folded NP-based ELISA and FMIA began with
checkerboard titrations of both the antigen and PDCoV
convalescent sera to determine optimum concentrations
of each. Depending on the calculation of signal to noise
ratios, optimum concentration of NP antigen was identi-
fied for coating of the ELISA plates and coupling FMIA
beads. We also identified optimum test serum dilutions
and blocking agents.
Development and diagnostic application of rabbit
antisera and monoclonal antibodies
Rabbits and mice were immunized with selected recom-
binant PDCoV proteins for production of hyperimmune
antisera and monoclonal antibodies (mAbs) as previ-
ously described [11–13]. Immunoglobulin isotyping of
the resulting mAbs was performed using a commercial
lateral flow assay (Serotec, Raleigh, NC).
Indirect fluorescent antibody assay
An IFA assay was developed for reference purposes
using pig serum of known serostatus. ST cells were
grown in cultures for 2 to 3 days to 80 % confluence on
96-well plates. Odd numbered lanes were infected with
PDCoV (approximately 1000 50 % tissue culture infect-
ive doses (TCID50)/ml) in MEM supplemented with 0.8
ug/ml TPCK-treated trypsin. The plates were incubated
for 18 to 24 h. then fixed with 50 % (vol/vol) acetone/
methanol for 20 min at −20 °C, air dried, and frozen
with a desiccant at −20 °C until they were used. Serum
dilutions of 1:20 and 1:40 were applied to infected and
control wells of the IFA plates and incubated 1 h. After
washing three times with 300 μl of phosphate buffered
saline (PBS), 40 μl of fluorescein isothiocyanate (FITC)-
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labeled goat anti-swine immunoglobulin G (41.7 g/ml;
KPL, West Chester, PA) was added to each well. The
plates were incubated at 37 °C for 1 h and washed with
PBS three times. The cells were examined for specific
fluorescence with an inverted microscope and a UV light
source (Nikon Eclipse TS100). Serum samples were
considered positive if PDCoV specific fluorescence was
observed at the 1:20 serum dilution.
Antibody detection indirect ELISA
The refolded PDCoV NP antigen-based indirect ELISA
was performed using methods previously described in
Okda et al. [13]. Briefly, alternate wells of Immulon 1B,
96-well, microtiter plates (Thermo Labsystems, Frank-
lin, MA) were coated for 1 h at 37 °C with 200 ng/well
of purified, refolded PDCoV-NP antigen diluted in
15 mM sodium carbonate-35 mM sodium bicarbonate,
antigen coating buffer (ACB) pH 9.6. Next, non-bound
antigen was poured off and the plates washed 3X with
PBS plus 0.05 % tween-20 (PBST), then the remaining
free-binding sites were blocked with 200 μl of sample
milk diluent ((SMD)-PBST plus 5 % nonfat dry milk)
and incubated overnight at 4 °C. Test and control sera
were diluted 1:50 in SMD, and 100 μl of the solution
was added to each well of a washed plate. The plates
were incubated for 1 h at 22 °C. Next, 100 μl of
biotinylated, FC-specific, goat anti-swine detection
antibody (Bethyl Laboratories, Montgomery, TX) was di-
luted 1:4000 in PBST and allowed to incubate at 22 °C for
1 h. Plates were washed 3X, then 100 μl of streptavidin-
horseradish peroxidase conjugate (Pierce, Rockford, IL, di-
luted 1:4000) was added and incubated for 1 h at 22 °C,
then washed and developed using TMB (Surmodics, Eden
Prairie, MN). Colorimetric development was stopped
using 2 N H2SO4, then OD’s were quantified spectro-
photometrically at 450 nm with a ELx800 microplate
reader (BioTek Instruments Inc., Winooski, VT). The raw
OD’s were normalized and the corrected S/P values were
calculated as follows: S/P = (OD of sample - OD of buf-
fer)/(OD of positive control - OD of buffer).
The optimal dilution of the recombinant protein and
secondary detection antibody was determined by a
checkerboard titration that gave the highest signal to
noise ratio. In addition, a single lot of pooled convales-
cent serum from PDCoV infected pigs was used to gen-
erate quality control standards that gave high, medium
and low Sample to Positive (S/P) values. The negative,
low and medium samples served as internal quality
standards while the high standard served as a serum
constant to mathematically calculate S/P values of in-
dividual unknowns. For the ELISA, a high positive S/
P = 0.8–1.0; medium S/P = 0.6–0.8; low S/P = 0.4–0.6;
and negative S/P < 0.2.
Microsphere coupling and FMIA procedure
The coupling of purified, recombinant, refolded PDCoV-
NP antigen to fluorescent microspheres was performed
using a two-step, carbodiimide coupling reaction as pre-
viously described [14]. Prior to performing large scale
coupling reactions for test validation, the optimization of
the amount of antigen used was obtained by performing
a checkerboard titration of antigen-coupled micro-
spheres against a two-fold titration of swine serum. It
was found that initiating a coupling reaction having
12.5ug of purified protein per 3.125 × 106 microspheres
was optimal in obtaining the highest signal-to-noise
fluorescence ratio. The performance of the FMIA test
was described in detail previously by Okda et al. [11]. In
the initial optimization of the FMIA test, we performed
two-fold serial dilutions of swine serum and concluded
that a dilution of 1:50 provided the highest signal-to-
noise ratio. For the generation of sample fluorescence,
antigen-coupled microsphere/antibody complexes were
analyzed through a dual-laser Bio-Rad Bio-Plex 200 in-
strument. The median fluorescent intensity (MFI) for
100 microspheres corresponding to each individual bead
analyte was recorded for each well. All reported MFI
measurements were normalized by calculating individual
S/P values using the following formula: S/P =MFI of
sample - MFI of buffer control/MFI of high positive
control - MFI of buffer control. The buffer control
equated to the background signal determined from the
fluorescence measurement of antigen-coated beads.
Lastly, a single lot of pooled convalescent serum from
PDCoV infected pigs was used to generate quality con-
trol standards that gave high, medium and low S/P
values. The negative, low and medium samples served as
internal quality standards while the high standard served
as a serum constant to mathematically calculate S/P
values of individual unknowns. For the FMIA, a high
positive S/P = 0.8–1.0; medium S/P = 0.6–0.8; low S/P =
0.4–0.6; and negative S/P < 0.2, is consistent with the
data of the ELISA standards.
Antibody capture efficacy comparison between refolded
vs linear PDCoV-NP antigen
An antibody capture titration assay was employed to
compare the efficacy of refolded vs. linear antigen to
capture anti-PDCoV-NP specific antibody in swine
serum. Wells of a 96-well microtiter plate were coated
with 10-fold decreasing concentrations of either linearly
expressed or refolded PDCoV-NP antigen in ACB,
pH 9.6., then allowed to incubate for 1 h at 37 °C. Each
well was then blocked with 200 μl of SMD and allowed
to incubate overnight at 4 °C. The following day, the
plates were washed 3X with 300 μl of PBST. Well char-
acterized positive control sera having a “high” positive
OD was diluted 1/50 in SMD, mixed, and 100 μl of the
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solution was added to each well. The ELISA was contin-
ued pursuant to the stated protocol and the OD was
recorded at each titration point, then a logarithmic re-
gression curve was generated. Relative capture efficien-
cies for each antigen-coated well was determined by
analyzing the OD at each dilution point and position
under the linear portion of the curve.
Assay validation
(i) Cutoff determination, DSe and DSp. To accurately
assess the DSe and DSp of the assays, the assays
were validated using known seronegative and
seropositive samples from distinct animal
populations. The expected positive samples used
were field serum samples submitted to the ADRDL
from herds previously testing PDCoV positive by
PCR. Expected negative samples included archived
experimental serum collected prior to 2009 and field
samples from high-health herds with no known
history of PDCoV exposure. Receiver operating
characteristic (ROC) analysis was performed using
MedCalc version 11.1.1.0 (MedCalc software,
Mariakerke, Belgium).
(ii)Measurement of repeatability. The repeatability of
the FMIA and ELISA was assessed by running the
same lot of internal quality control serum standards
multiple times on the same plates and on different
plates over time. The intra-assay repeatability was
calculated using 36 replicates on a single plate and
then repeated over a 3-day period for inter-assay
repeatability assessment. Each assay was run in a
single-plex format, and median fluorescence
intensity values were expressed as percent coefficient
of variation (CV) for repeated measurements.
Percent CV was calculated using a method described
earlier [15].
Statistical analyses and measurement of testing
agreement
Multiple comparison, inter-rater agreement (kappa meas-
ure of association) was calculated among all three tests
(ELISA, FMIA and IFA) using IBM, SPSS version 20 soft-
ware (SPSS Inc., Chicago, IL). The sample cohort used in-
cluded a set of archived serum samples collected from
PDCoV “positive testing” experimentally infected pigs
over time and from archived experimental control unin-
fected PDCoV “negative testing” animals. The interpret-
ation of kappa can be rated as follows: Kappa less than
0.0, “poor” agreement; between 0.0 and 0.20, “slight”
agreement; between 0.21 and 0.40, “fair” agreement; be-
tween 0.41 and 0.60, “moderate” agreement; between 0.61
and 0.80, “substantial” agreement; and between 0.81 and
1.0, “almost perfect” agreement [16].
Validation of the tests was performed by ROC analysis
using Medcalc statistical software. Correlations between
the tests and scatterplots for seroconversion were per-
formed using SPSS 20.
Results
Expression of recombinant full-length nucleoprotein
The full-length NP of PDCoV was cloned and expressed
in E. coli as a polyhistidine fusion protein. Antigen purity
was then evaluated using SDS-PAGE in which the His-
tagged recombinant NP migrated through the gel accord-
ing to its predicted molecular mass of 41 kDa upon
staining with Coomassie brilliant blue R250 (Fig. 1a). The
recombinant protein was expressed in the form of insol-
uble inclusion bodies. It was purified by Nickel-NTA affin-
ity column chromatography and yielded a calculated
concentration of approximately 10 mg PDCoV-NP/liter of
2XYT medium and having a purity greater than 95 % as
measured by the Lowry protein assay. The protein was
subsequently refolded back to its soluble, conformational
structure and its specificity was tested via Western blot-
ting (Fig. 1b). The figure illustrates the migration pattern
and antigen specificity of the refolded PDCoV-NP/poly-
histidine fusion protein as compared to the adjacent lane
loaded with semi-purified, concentrated PDCoV. Both the
rPDCoV-NP and native virus are recognized with equal
intensity by a PDCoV-NP-specific monoclonal antibody
(SD55-197) developed in our laboratory. Also, the recom-
binant nucleocapsid protein is shown to have a higher
molecular mass than the native virus nucleocapsid due to








Fig. 1 Purification and antigen specificity of PDCoV-NP antibody
capture antigen. a Coomassie blue staining of E. coli expressed and
purified PDCoV-NP antigen used to coat ELISA microtiter plates and
FMIA microspheres. Molecular weight ladder MW and PDCoV-NP
(41 kDa). b Western blot showing antigen specificity of recombinant,
refolded PDCoV-NP/polyhistidine fusion protein probed with mAb SD-
55-197 (Lane 1). Lane 2 was loaded with semi-purified, concentrated
PDCoV strain HKU15/Michigan/8977/2014 then probed with
mAb SD-55-197
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Experiments were conducted to assess the immunore-
activity of refolded vs non-refolded PDCoV-NP antigen
used for both tests. Specifically, an antibody capture ti-
tration ELISA was employed to compare the ability of a
refolded and non-refolded version of the antigen to cap-
ture antibodies within swine serum. The immunoreactiv-
ity of antigen was determined by end-point titration and
relative absorbance values as we observed differences in
immunoreactivity based upon the conformational state
of antigen tested. Figure 2 demonstrates in a dose-
dependent fashion, that as the concentration of each
antigen coated well decreases, the refolded antigen im-
parts a greater degree of antibody capture efficacy of
swine antibodies than the non-refolded version. Spe-
cifically, a 27 fold difference was calculated at the
end of the linear portion of the curve indicating that
the refolded protein maintained a marked enhance-
ment of immunoreactivity resulting in a greater dy-
namic range of the assay.
Fluorescent microsphere immunoassay and indirect ELISA
development
(i) Establishment of control standards: ELISA and
FMIA test reference standards for PDCoV were
developed for each of the respective prototype
assays (Fig. 3a and b). A control high positive
standard was established by pooling several lots of
serum collected from convalescent, seropositive pigs,
and used to mathematically calculate S/P values of
each assay. The medium and low positive samples
served as internal quality control standards. The
negative standard was pooled from a set of known
seronegative pigs from a herd with no known prior
PDCoV infection that also tested negative by
PDCoV IFA and virus neutralization.
(ii)Test optimization: A series of coupling processes
were performed using a two-fold titration of antigen
to determine the optimum coupling concentration.
A total of 3.125 x106 beads, were incubated with
various concentrations (100 μg, 50 μg, 25 μg, and
12.5 μg) of purified NP. Based upon the highest
signal-to-noise ratio reflecting the detection of
PDCoV-specific antibodies in standard serum,
12.5 μg per reaction was the optimal concentration
for microsphere coupling. ELISA microtiter plates
were coated with an optimized concentration of
200 ng antigen per well.
Testing the re-folded, NP antigen-based ELISA and
FMIA began with checkerboard titration of both antigen
and PDCoV convalescent and naïve swine serum to de-
termine the optimum signal-to-noise ratio of each test.
We also identified optimum test serum dilutions and
blocking agents. The optimal serum dilution of each
assay was determined by diluting serum samples two-
fold in their respective blocking/detergent buffer diluent.
For both the FMIA and ELISA, a serum dilution of 1:50
was shown to produce an optimal signal-to-noise ratio
(Fig. 3c and d). Testing field samples of known sero-
logical status was performed to gauge initial sensitivity
of the assay. Our results showed a positive to negative
sample ratio (P/N) of greater than 16-fold with ELISA
and a P/N of greater than 40-fold with FMIA. The P/N
is a relative measure of PDCoV antibody concentration
between seropositive and seronegative samples. Having a
diagnostic P/N of greater than 10 is highly desirable with
any serological assay.
Assessment of test repeatability
The intra-assay repeatability was calculated for 36 repli-
cates on a single plate and then repeated over a 3-day
period for inter-assay repeatability assessment. Internal
control serum standards were used to determine the
precision of each FMIA and ELISA. The inter-assay and
intra-assay repeatability of each test demonstrated a co-
efficient of variation of less than 8.6 %. These results
confirmed that the serological tests are highly repeatable
in diagnostic applications.
Validation methods and cutoff determination
ROC analysis of both FMIA and ELISA was per-
formed using MedCalc software to calculate an opti-
mized cutoff value that maximizes the DSe and DSp
of each assay. Using known seronegative and sero-
positive serum samples (n = 940), the expected posi-
tive samples used were submitted as field serum
Fig. 2 Antibody capture efficacy comparison between refolded vs
linear PDCoV-NP. An ELISA antibody capture titration assay was
employed to compare the ability of refolded vs. linear antigen to
capture anti-PDCoV-NP specific antibody in swine serum. Wells of a
96-well microtiter plate were coated with decreasing concentrations
of either linearly expressed or refolded PDCoV-NP antigen. Refolded
antigen demonstrated greater dynamic range of the assay and
capture efficacy of swine antibody
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samples (n = 311) from herds previously testing
PDCoV positive by PCR. Expected negative samples
included archived experimental serum collected prior
to 2009 (n = 108) and field samples from high-health
herds with no known history of PDCoV exposure (n
= 521). ROC analysis was performed and DSe and
DSp were shown to be 96.1 and 96.2 % respectively
for the ELISA; and 95.8 and 98.1 % respectively for
the FMIA (Fig. 4). The similar cutoff values of both
assays confirm the utility of these new diagnostic tests
to aid in the control and surveillance of PDCoV
outbreaks.
Evaluation of the kinetic swine antibody response in
serum
Once validated, the assays were used to evaluate the kin-
etic antibody response over time using serum collected
from experimentally infected pigs over weekly intervals.
Serological responses detected by the PDCoV ELISA
and FMIA following challenge show seroconversion be-
tween days 8 and 14 DPI (Fig. 5). Both assays demon-
strate a similar dynamic range using the same serum
samples and “high” positive standard from which the S/P
values are calculated. However, the FMIA appears to de-
tect a slightly higher level of antibody over a longer
A B
C D
Fig. 3 Production and reactivity of serological reference standards and internal quality control standards for both ELISA (a) & FMIA (b). Reference
serum standards were titrated 2-fold in antigen coated wells at a fixed concentration [250 ng/well] in order to gauge a maximum signal-to-noise ratios
for each assay c ELISA, and d FMIA. Arrows indicate the optimal serum dilution that resulted in the greatest positive to negative (P/N) ratio for the test
Fig. 4 Receiver operator characteristic (ROC) validation and determination of diagnostic sensitivity (DSe) and specificity (DSp) of the PDCoV-NP ELISA
and FMIA assays. DSe and DSp were calculated using serum samples from known PDCoV-infected and known PDCoV-uninfected populations. ROC
analysis was performed using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the dot plot on the left represents the
negative population, and the plot on the right represents the positive population. The horizontal line bisecting the dot plots for each figure represents
the tentative cutoff value that gives the optimal DSe and DSp
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period of time at days 35 and 42 post infection. Add-
itional testing of seroconversion included serum samples
collected from a group of 30 piglets near the time of
initial field exposure to PDCoV then 28 days later.
Figure 6 shows clear seroconversion to the naturally
circulating virus within the 28 day time-frame using
the same diagnostic cutoff values previously deter-
mined by ROC analysis.
Measurement of statistical testing agreement
Multiple comparison, inter-rater (kappa) agreement is a
statistical measure of testing agreement, and was calcu-
lated among all three tests (ELISA, FMIA & IFA) using
629 positive testing and 311 negative testing serum
samples. Statistical comparison calculated kappa values
to be 0.940 between FMIA and IFA, 0.902 between
ELISA and IFA, and 0.914 between ELISA and FMIA
(Table 1). Because all three diagnostic platforms had
kappa values above 0.81, it demonstrates that the
tests are in “almost perfect” agreement with each
other according to the interpretation of kappa by
Landis et al. [16].
Cross reactivity
Serological cross reactivity testing was performed be-
tween PDCoV and other closely related swine corona-
viruses. There was no cross reactivity among the 93
TGEV positive serum samples, 20 PRCV positive serum
samples, 167 PEDV field positive serum samples and 84
PEDV experimentally positive serum samples tested via
ELISA and FMIA (Table 2). The data show mean OD
and MFI readings from ELISA and FMIA tests, respect-
ively. The lack of cross reactivity between PDCoV and
aforementioned alphacoronavirus species was also con-
firmed via western blotting using seropositive, convales-
cent sera from individual pigs (data not shown).
Development of reagents for detection of PDCoV antigen
in diagnostic tests
Both denatured and refolded versions of the NP were
used to immunize rabbits for hyperimmune serum and
mice for monoclonal antibody production. Rabbit hyper-
immune sera specifically recognize the NP and can be
used in indirect fluorescent antibody staining at dilutions
of 1:1000 to 1:5000. In addition, the polyclonal antisera
was used successfully in immunohistochemical staining
Fig. 5 Serum antibody kinetic time course evaluation. Antibody kinetic responses were calculated for the ELISA and FMIA tests using serum
collected weekly over six weeks from experimentally infected pigs. Serological responses detected by PDCoV ELISA and FMIA tests show














Fig. 6 ELISA (a) and FMIA (b) results from a group of 30 piglets sampled near the time of initial PDCoV field exposure then 28 days later. Both
assays show clear seroconversion to naturally circulating PDCoV. The horizontal line between both positive and negative testing samples shows
the diagnostic cutoff value for each test previously determined by ROC analysis
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procedures for the detection of PDCoV antigen in intes-
tinal tissues (Fig. 7b). The resulting monoclonal anti-
bodies all recognized native viral protein in infected ST
cells demonstrated by bright cytoplasmic immunofluor-
escent staining (Fig. 7a) and within intestinal enterocytes
stained immunohistochemically (Fig. 7c).
Discussion
As a recently identified pathogen, the impact of PDCoV
on the swine industry is not yet fully understood. Field
observations and recent research studies have suggested
that the virus can cause substantial morbidity and mor-
tality in nursing piglets [5–7, 17]. Specific antibody-
based reagents and serological tests are essential for the
further study and control of PDCoV, as well as the
differentiation of PDCoV infection from other related
coronaviruses such as PEDV or TGEV.
Therefore, the primary objective of this study was to
develop an initial generation of antibody-based diagnos-
tic reagents and serological assays for the further study
of PDCoV, including NP-based indirect ELISA and
FMIA tests that were developed and validated for diag-
nostic applications. Specific antibody-based reagents
were also not yet available for PDCoV so monoclonal
antibodies against selected PDCoV structural proteins
were developed. The tools developed during the course
of this study can be applied to many ongoing and future
studies to better understand and control PDCoV.
The new monoclonal antibody reagents described here
should be of substantial value in the detection of PDCoV
antigen in a variety of applications including: early verifi-
cation of virus isolation attempts and virus titrations;
immunohistochemistry staining of fixed tissues; develop-
ment of neutralization assays; fluorescent antibody stain-
ing of fresh tissues; development of field-based antigen
capture assays such as lateral flow devices; and ELISA
applications (competitive ELISA and antigen capture).
Through extensive testing via ELISA (over 364 samples)
and Western blot analysis, we were not able to demon-
strate any cross-reactivity with other major swine coro-
naviruses including PEDV, PRCV and TGEV. However,
since many described deltacoronaviruses of other species
have not yet been adapted to cell culture replication or
fully characterized, we do not yet know if these reagents
may cross-react with other members of the genus.
Several new serological assays for detection of anti-
body responses to PDCoV were developed during the
course of this study. The ELISA and FMIA tests were
based on a recombinant nucleoprotein antigen since this
protein is highly conserved among PDCoV isolates. In
addition, the NP is known to be the most abundant viral
protein within host cytoplasmic compartments [18]. The
highly immunoreactive PDCoV-NP interacts with itself
to form non-covalently linked oligomers and associates
with the viral genome to serve as the architectural basis
of the ribonucleoprotein complexes during virus assem-
bly [19]. These reasons provided the rationale for its
utility as a target antigen for the serodiagnosis of
PDCoV in indirect ELISA and FMIA platforms.
Antibody responses to the nucleoprotein of corona-
viruses are very robust and have been reported to appear
as soon as 7–9 days post infection. We originally hy-
pothesized that antibody reactivity to PDCoV may be
conformationally dependent so we designed an experi-
ment to determine whether NP specific immunodomi-
nant epitopes tend to be present in greater abundance
on conformationally or linearly expressed antigen. A
refolded version of the NP was used as an antigen in
both assays as it was shown to impart a higher degree of
immunoreactivity than its unfolded, linear counterpart.
This phenomenon was also observed by Johnson et al.
[20] whereby the authors compared reactivity differences
among single point serum titrations to provide a surro-
gate measure of antibody titer. They showed that the en-
hancement of immunoreactivity of PRRSV-N and nsp1
was completely dependent on refolding, and the reactiv-
ity of nsp2P was enhanced by twofold. Furthermore we
confirmed their observations that there is a loss of im-
munoreactivity when the linear protein (solubilized in
8 M urea) was dialyzed in PBS prior to coating on mi-
crotiter plates or used for coupling to FMIA micro-
spheres. This may indicate that using an antigen in its
more native conformational state may present a higher
number of immunoreactive epitopes that are able to
Table 2 Serological cross reactivity testing among related swine
coronaviruses
TGEV PRCV PEDV
ELISA Mean OD 0.097 0.132 0.074
FMIA Mean FI 0.024 0.016 0.032
Total No. serum samples tested 93 20 251
Table 1 Evaluation of statistical testing agreement among three
serological testing platforms
FMIA Indirect ELISA IFA
IFA 0.940 0.902 1
Indirect ELISA 0.914 1 0.902
FMIA 1 0.914 0.940
Number positive serum samples 311 311 315
Number negative serum samples 629 629 625
Total 940 940 940
Multiple comparison, inter-rater agreement (kappa association) were calculated
among all three tests, IFA, indirect ELISA and FMIA. Kappa values shown
represent a statistical measure of test agreement and were calculated using
MedCalc version 11.1.1.0
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capture a larger percentage of PDCoV-NP antibodies.
Therefore, the production of a well purified, refolded
recombinant protein maintained in a near-native con-
formation was required for the production of an effi-
cacious assay.
Both assays provide the capability of high-throughput
testing with reasonable DSe and DSp. ROC analysis was
performed for both assays demonstrating DSe of greater
than 95 %. The FMIA demonstrated good DSp of 98.1 %
while the ELISA showed a slightly lower DSp of 96.2 %.
Inter-rater (kappa) agreement, a statistical measure of
test agreement demonstrated a significant level of
agreement among the IFA, ELISA and FMIA. Further-
more, each of the antibody-capture assays was validated
using a large number of well characterized serum sam-
ples (n = 940) based upon the suggested 5-stage valid-
ation methods of Jacobson, which is supported by the
office International des Epizooties [21].
Although preliminary DSe and DSp determinations for
the first generation serological assays described here
were slightly less than ideal, these new assays should
provide valuable tools for assessment of PDCoV expos-
ure on a herd level. One explanation for the approxi-
mately 95–96 % DSe values determined to date may be
related to selection of the presumed positive field popula-
tions used for test validation. In this case, the initial stages
of validation relied on characterizing the assay using
known serum samples from experimentally infected pigs.
Because this was the only sera of known serostatus we
had at our disposal, we believe that the resulting initial
ROC characteristics were of sufficient value to begin test-
ing samples from other sources believed to not have been
exposed to PDCoV and from field sources known to have
seroconverted to PDCoV within a specific time frame. By
following the methodology outlined by Jacobson [21] in
which he recommends the inclusion of these initial ROC
cut-off values from experimentally infected pigs, we dem-
onstrated similar assay characteristics on chosen field
samples which substantiated our final cut-off value of the
assay. These sample sets were collected at approximately
3 weeks after initial diagnosis of PDCoV by PCR. It is pos-
sible that PDCoV may not move through a herd at the
very rapid rate seen with PEDV. Therefore, some animals
in some herds may not have been infected until a week or
more after initial detection in the population, resulting in
delayed seroconversion in a percentage of the presumed
positive population. Likewise, since the initial origination
and distribution of PDCoV in the U.S. is not fully under-
stood at this time, it is possible that a small percentage of
our presumed seronegative population may have been
subject to prior exposure. Many of the samples in our
presumed negative population were archived samples
collected prior to 2009. However, some originated
from recent field submissions from high health, biose-
cure herds with no clinical or PCR evidence of prior
PDCoV or PEDV exposure. The observed DSp values
Fig. 7 Development of reagents used for indirect fluorescent antibody (IFA) testing and immunohistochemical (IHC) staining of PDCoV infected cells.
Indirect fluorescent antibody staining of PDCoV infected ST cells with PDCoV anti-nucleoprotein monoclonal antibody SD-55-24 [a, 100X magnification].
Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein rabbit polyclonal hyperimmune sera [b, 100X magnification].
Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein monoclonal antibody 55–197 [c, 100X magnification].
Uninfected control showing hematoxylin staining of luminal, intestinal brush-border cross section [d, 100X magnification]
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of approximately 98 % for FMIA and 96 % for indir-
ect ELISA are within the expected range for first gen-
eration assays using these test formats. Apparent false
positive reactions could also be due to an epitope on
the expressed antigen having commonality with an-
other low prevalence infectious agent or due to low
levels of residual E. coli protein contaminants in the
purified antigen preparations.
Recently, Thachil et al. [8], developed an indirect
anti-PDCoV IgG enzyme-linked immunosorbent assay
based on the putative S1 portion of the spike protein
and evaluated it using a total of 968 tested serum
samples. Although it is a reasonably sensitive (91 %)
and specific (95 %) test, there is room for other ELI-
SAs utilizing other target antigens, such as the NP of
PDCoV, to serve as primary serological surveillance
or confirmatory assays. As noted in Thachil’s re-
search, serum samples collected in 2010 were found
positive for PDCoV antibody by their ELISA, but not
those collected in 2011 and 2012. This was controver-
sial because PDCoV was not thought to be circulating
in North America in pigs before its identification in
late 2013 [9]. It will be very beneficial to have con-
firmatory assays to validate this finding. Additional
screening of archived historical swine serum samples
using multiple serological assays may provide further
insight into the origin and epidemiology of PDCoV in
North America.
Conclusions
The monoclonal antibody reagents developed here
provide important research and diagnostic tools for
the industry. They are valuable for fluorescence and
immunohistochemical staining methods associated
with diagnostic and pathogenesis studies. The sero-
logical assays allow the detection of antibodies devel-
oped in response to PDCoV infection. The PDCoV
indirect ELISA and FMIA will allow high-throughput
screening of swine serum samples. These tests should
be adequately optimized and validated for sero-
surveillance on a herd level, but further improvement
is needed for full confidence on an individual animal
basis. The IFA or other tests may be required for
confirmation of individual unexpected results. Work
is ongoing to further validate these assays and to
adapt them to different sample matrices such as milk
or oral fluid samples. Since lactogenic immunity is
likely critical for protection of nursing piglets, these
assays will be modified for detection of IgA as well.
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